Literature DB >> 23292876

Qualitative and quantitative analysis of cinobufacini injection using rapid separation liquid chromatography coupled with quadrupole-time-of-flight mass spectrometry and HPLC-photodiode array detection, a feasible strategy for the quality control of Chinese medicine injections.

Haiyu Zhao1, Xu Wu, Hongjie Wang, Bo Gao, Jian Yang, Nan Si, Baolin Bian.   

Abstract

Cinobufacini injection, prepared from the skin of Bufo bufo gargarizans Cantor, has presented its significant effects on the treatment of hepatitis and various cancers in the clinic. However, as an unclear complex chemical system, the optimization of its quality control markers has been a long-term challenge. In present study, a feasible strategy integrated markers screening, determination, and statistical analysis was efficiently proposed, especially for the undefined Chinese medicine injections. First, rapid separation LC-quadrupole-TOF-MS method was applied in the identification of 19 major compounds in the cinobufacini injection for the first time. Further, nine high-level contents active compounds were selected as quality control markers for the quantification analysis. An acceptable and validated determination method was established in 17 batches of cinobufacini injection by HPLC-photodiode array detection method, including linear regression relationship (r(2), 0.9996-1), precisions (RSD, 0.02-1.35%), repeatability (RSD, 0.05-1.97%), stability (RSD, 0.1-3.85%), and recovery (95.88-104.89%). Each analyte was detected at its maximum ultraviolet spectra wavelength. Finally, based on the quantification results, principal component analysis was performed on the quality assessment of cinobufacini injections. This three-step strategy provides a newly feasible solution for the quality control of Chinese medicine injections.
© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23292876     DOI: 10.1002/jssc.201200762

Source DB:  PubMed          Journal:  J Sep Sci        ISSN: 1615-9306            Impact factor:   3.645


  6 in total

1.  Clinical efficacy and safety of Huachansu injection combination with platinum-based chemotherapy for advanced non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials.

Authors:  Xinmei Tan; Xueyan Liang; Jiaxi Xi; Sitong Guo; Mingyu Meng; Xiaoyu Chen; Yan Li
Journal:  Medicine (Baltimore)       Date:  2021-09-10       Impact factor: 1.817

2.  Evaluation of Bufadienolides as the Main Antitumor Components in Cinobufacin Injection for Liver and Gastric Cancer Therapy.

Authors:  Xiaolu Wei; Nan Si; Yuefei Zhang; Haiyu Zhao; Jian Yang; Hongjie Wang; Lianmei Wang; Linyu Han; Baolin Bian
Journal:  PLoS One       Date:  2017-01-12       Impact factor: 3.240

Review 3.  Meta-Analysis of Therapy of Cinobufacini Capsule Adjunct with First-Line Platinum-Based Chemotherapy for the Treatment of Advanced NSCLC.

Authors:  Wenpan Peng; Yong Xu; Fanchao Feng; Cheng Gu; Zhichao Wang; Di Han; Xianmei Zhou; Hailang He
Journal:  Evid Based Complement Alternat Med       Date:  2021-08-21       Impact factor: 2.629

4.  Comparative Pharmacokinetics of Cinobufacini Capsule and Injection by UPLC-MS/MS.

Authors:  Ming Li; Yanhong Qin; Zhe Li; Jinshuai Lan; Tong Zhang; Yue Ding
Journal:  Front Pharmacol       Date:  2022-07-18       Impact factor: 5.988

Review 5.  Is Huachansu Beneficial in Treating Advanced Non-Small-Cell Lung Cancer? Evidence from a Meta-Analysis of Its Efficacy Combined with Chemotherapy.

Authors:  Bingduo Zhou; Fengying Wu; Lin Yuan; Zhulei Miao; Shengliang Zhu
Journal:  Evid Based Complement Alternat Med       Date:  2015-08-11       Impact factor: 2.629

6.  Network Pharmacology Study on the Pharmacological Mechanism of Cinobufotalin Injection against Lung Cancer.

Authors:  Yun Mao; Xi Peng; Peng Xue; Dianrong Lu; Linlu Li; Shijie Zhu
Journal:  Evid Based Complement Alternat Med       Date:  2020-02-17       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.